Sorrento Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Sorrento Therapeutics CEO'su Henry Ji, Sep2012 tarihinde atandı, in görev süresi 10.67 yıldır. in toplam yıllık tazminatı $ 10.07M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.1% maaş ve 79.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.84% ine doğrudan sahiptir ve bu hisseler € 1.30M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 6.8 yıldır.

Anahtar bilgiler

Henry Ji

İcra Kurulu Başkanı

US$10.1m

Toplam tazminat

CEO maaş yüzdesi	20.1%
CEO görev süresi	10.7yrs
CEO sahipliği	0.8%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	6.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Henry Ji'un ücretlendirmesi Sorrento Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2023	n/a	n/a	-US$672m
Dec 31 2022	US$10m	US$2m	-US$573m
Sep 30 2022	n/a	n/a	-US$494m
Jun 30 2022	n/a	n/a	-US$524m
Mar 31 2022	n/a	n/a	-US$472m
Dec 31 2021	US$20m	US$2m	-US$428m
Sep 30 2021	n/a	n/a	-US$355m
Jun 30 2021	n/a	n/a	-US$320m
Mar 31 2021	n/a	n/a	-US$231m
Dec 31 2020	US$158m	US$839k	-US$298m
Sep 30 2020	n/a	n/a	-US$290m
Jun 30 2020	n/a	n/a	-US$270m
Mar 31 2020	n/a	n/a	-US$249m
Dec 31 2019	US$8m	US$781k	-US$292m
Sep 30 2019	n/a	n/a	-US$279m
Jun 30 2019	n/a	n/a	-US$262m
Mar 31 2019	n/a	n/a	-US$279m
Dec 31 2018	US$5m	US$670k	-US$204m
Sep 30 2018	n/a	n/a	-US$105m
Jun 30 2018	n/a	n/a	-US$60m
Mar 31 2018	n/a	n/a	-US$378k
Dec 31 2017	US$2m	US$600k	US$9m
Sep 30 2017	n/a	n/a	-US$57m
Jun 30 2017	n/a	n/a	-US$39m
Mar 31 2017	n/a	n/a	-US$68m
Dec 31 2016	US$2m	US$600k	-US$61m

Tazminat ve Piyasa: Henry 'nin toplam tazminatı ($USD 10.07M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 793.15K ).

Tazminat ve Kazançlar: Henry 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Henry Ji (58 yo)

10.7yrs

Görev süresi

US$10,069,893

Tazminat

Dr. Henry H. Ji, Ph.D. serves as Director at Aardvark Therapeutics, Inc. since 2022. Dr. Ji serves as Executive Chairman of the Board at SCILEX Pharmaceuticals, Inc. Dr. Ji serves as Executive Chairman of...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Henry Ji	Chairman	10.7yrs	US$10.07m	0.84% € 1.3m
Elizabeth Czerepak	Executive VP	less than a year	US$922.24k	0% € 0
Brian Cooley	Senior Vice President of Corporate Communications & Lymphatic Drug Development BU	1.3yrs	Veri yok	Veri yok
Michael Royal	SVP & Chief Medical Officer	3.3yrs	US$557.04k	Veri yok
Alexis Nahama	Senior Vice President of Neurotherapeutics BU	3.3yrs	Veri yok	Veri yok
Mark Brunswick	Senior Vice President of Regulatory Affairs	3.3yrs	Veri yok	Veri yok
Shawn Sahebi	Senior Vice President of Commercial Operations	3.3yrs	Veri yok	Veri yok
Xiao Xu	President of ACEA	1.3yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim: 8STN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Henry Ji	Chairman	17.3yrs	US$10.07m	0.84% € 1.3m
David Lemus	Independent Director	5.6yrs	US$181.33k	0% € 0
Jaisim Shah	Director	9.7yrs	US$868.23k	0.021% € 32.0k
Tammy Reilly	Independent Director	less than a year	US$175.92k	0% € 0
Kim Janda	Chair of Scientific Advisory Board & Director	11.1yrs	US$82.50k	0% € 0
Yue Wu	Independent Director	6.8yrs	US$150.00k	0.00092% € 1.4k
Dorman Followwill	Lead Independent Director	5.6yrs	US$250.02k	0.00039% € 602.3

6.8yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 8STN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).

Sorrento Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors

Sorrento Therapeutics, Inc., Annual General Meeting, Apr 06, 2023

Less than half of directors are independent

Less than half of directors are independent

Sorrento Therapeutics, Inc., Annual General Meeting, Dec 15, 2022

Less than half of directors are independent

Recent updates

Final DIP Financing Approved for Sorrento Therapeutics, Inc.

Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors

Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R Mzl)

Sorrento Therapeutics, Inc. Announces Full Enrollment of Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), Second Generation Oral Mpro Inhibitor, as Standalone Treatment for COVID-19

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Therapeutics, Inc.(NasdaqCM:SRNE) dropped from S&P Biotechnology Select Industry Index

Sorrento Therapeutics Received Written Notice from the Staff of The Nasdaq Stock Market LLC

Sorrento Therapeutics, Inc., Annual General Meeting, Apr 06, 2023

Sorrento Therapeutics, Inc. Releases Unblinded Phase 1B Study Data of Its Oral Main Viral Protease Inhibitor, OVYDSO™ (STI-1558) in Covid Patients

Sorrento Therapeutics Receives FDA Clearance to Initiate Clinical Trials with A Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus

Sorrento Therapeutics, Inc. Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented At Asian Congress of the European Society for Medical Oncology (Esmo)

Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from A Phase IB Study in China with STI-1558

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.40 loss in 3Q 2021)

Less than half of directors are independent

Sorrento Therapeutics, Inc., Annual General Meeting, Dec 15, 2022

Sorrento Therapeutics, Inc. Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with Sti-1558, an Oral Mpro Inhibitor as A Standalone Oral Treatment and Prevention of Covid-19 Without the Need for A Ritonavir Booster

Sorrento Therapeutics, Inc. Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures At 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcutaneous Injections

Sorrento Therapeutics, Inc. Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer

Sorrento Therapeutics, Inc. Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Therapeutics, Inc. Announces the Completion of the SAD Portion of the Phase 1 Study of Its Oral Main Viral Protease (Mpro) Inhibitor, the STI-1558

Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19

Sorrento Therapeutics, Inc. Announces First Subject Dosed in A Phase I Clinical Study of Sti-1558, an Oral Mpro Inhibitor as A Standalone Treatment and Prevention of Covid-19 Without Co-Administration of Ritonavir Booster

Less than half of directors are independent

Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors

Sorrento Therapeutics, Inc. Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)

Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern

Sorrento Therapeutics, Inc. Announces That It Has Received Clearance from the FDA for Its Investigational New Drug Application for Intravenous (Iv) Sti-9167

Sorrento Therapeutics Announces the Appointment of Laura Hamill to Its Board of Directors

Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients with Severe Pneumonia Due to Covid-19

Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure

Sorrento Therapeutics, Inc. announced delayed annual 10-K filing

Sorrento Therapeutics, Inc Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) acquired an unknown majority stake in Zhengzhou Fortune Bioscience Co., Ltd..

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) completed the acquisition of Virex Health, Inc.

Sorrento Announces its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron

Sorrento Therapeutics, Inc. Announces Covishield (STI-9167), A Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346K) Variants of Sars-Cov-2

Sorrento Therapeutics, Inc. Announces Completion of Enrollment in US Phase 2 Clinical Trial for Covi-Drops and Achievement of Interim Analysis Threshold in the UK

Brazilian Health Regulatory Agency Authorizes Sorrento Therapeutics, Inc.'s Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)

Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors

Sorrento Therapeutics, Inc. Begins Enrollment in Phase 2 Trial of Resiniferatoxin for the Treatment of Pain Due to Knee Osteoarthritis (OA)

Sorrento Announces Publication of Series of Novel Sars-Cov-2 Main Protease (Mpro) Inhibitors for Potential Treatment of Covid-19 Patients Infected with Sars-Cov-2 Variants of Concern, Including Omicron

Insufficient new directors

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.33 loss in 3Q 2020)

Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test

Sorrento Therapeutics, Inc. Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients

Sorrento Therapeutics, Inc. Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device

Sorrento Therapeutics, Inc. Publishes Positive Initial Results of Sofusa® Lymphatic Drug Delivery System in A Phase 1B Rheumatoid Arthritis Study Using Enbrel

Sorrento Announces its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern

Sorrento Therapeutics, Inc. Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.36 loss in 2Q 2020)

Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma

Sorrento Therapeutics, Inc. Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS

Sorrento Therapeutics, Inc.(NasdaqCM:SRNE) dropped from Russell 3000E Index

Sorrento Therapeutics, Inc. Receives Emergency Use Authorization Approval and Import License from COFEPRIS for COVI-STIX and Plans Product Launch with Initial Shipments in July

Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of Third Quarter of 2021

Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting

Sorrento Announces Positive Results from Its License Partner, Kelun, on A Phase I Study of Safety and Pharmacokinetics of A166, A Novel Her2 ADC for Advanced Her2 Positive Breast Cancers

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) completed the acquisition of ACEA Therapeutics, Inc. for approximately $550 million.

Brazilian Health Regulatory Agency Authorizes Sorrento Therapeutics, Inc.'s Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients with Acute Respiratory Distress Syndrome

First quarter 2021 earnings released: EPS US$0.009 (vs US$0.36 loss in 1Q 2020)